Kymera Results Presentation Deck

In Vivo Inhibition of Disease-Relevant Plasma Cytokines and Acute Phase Reactants by KT-474 in HS/AD Patients IL-6 Analyte IL-6t CRPt IL-1B SAAT Mean Max* AD Mean Max* HS (n) (n) -56% (3) ΝΑ -36% (7) -51% (4) *Max % reduction through Day 42 +Analysis performed only on patients with values >ULN at baseline IL-6, IL-13 and CRP are high sensitivity assays KYMERA ©2022 KYMERA THERAPEUTICS, INC. -63% (8) -58% (5) -48% (8) -41% (10) Percent Change from Baseline 50 O -50 0 7 ed 14 TICH 28 Days + 35 AD (N=3) HS (N=8) 42 PAGE 41

View entire presentation